

Original Article

Larvicidal Effects of Metabolites Extracted from *Nocardia* and *Streptomyces* Species against the Fourth Larval Stage of *Anopheles stephensi* (Diptera: Culicidae)

Marjan Seratnahaei¹, *Seyyed Saeed Eshraghi^{1,2}, Parviz Pakzad³, *Alireza Zahraei-Ramazani⁴, Mehdi Yaseri⁵

¹Department of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran

²Department of Pathobiology, School of Public Health, Tehran University of Medical Science, Tehran, Iran

³Department of Microbiology, faculty of Basic Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

⁴Department of Biology and Vector Control of Diseases, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

⁵Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding authors: Dr Seyyed Saeed Eshraghi, E-mail: eshrags@tums.ac.ir, Dr Alireza Zahraei-Ramazani, E-mail: azahraei@tums.ac.ir

(Received 11 Apr 2022; accepted 21 Jun 2023)

Abstract

Background: Larvicidal agents can be produced using microbial resources, which are environmentally friendly, biodegradable, and economical. The study's goal was to evaluate the larvicidal activity of metabolites isolated from *Nocardia* (*N. fluminea*, *N. soli* and *N. pseudobrasiliensis*) and *Streptomyces* (*S. alboflavus*) bacterial species against *Anopheles stephensi*.

Methods: Four metabolites isolated from *Nocardia* and *Streptomyces* strains were examined for larvicidal activity. The experiments were performed for 24, 48, and 72 hours. 300, 350, 400, 450, 500, 550, and 600 µl of *Actinobacteria* metabolites were added to 100 cc of dechlorinated water. Fourth-stage larvae were placed in dechlorinated water as a control. LC₅₀ and LC₉₀ were calculated using toxicity data and analyzed.

Results: All metabolites had a statistically significant influence on mosquito larvae (P < 0.05). At 24, 48, and 72 hours, the LC₅₀ for N2 (*N. fluminea*) was 417, 386, and 370 ppm, respectively, and the LC₉₀ was 650, 595, and 561 ppm. Moreover, LC₅₀ for N4 (*N. soli*) was 389, 376, and 347 and LC₉₀ were 591, 565, and 533 and LC₅₀ for N5 (*N. pseudobrasiliensis*) was 390, 357, and 341 ppm and LC₉₀ were 589, 532 ppm. In addition, LC₅₀ for S921 (*S. alboflavus*) was 484, 416, and 382 ppm, and LC₉₀ was 701, 612, and 574 ppm.

Conclusion: The four bacterial metabolites tested in our study were found to have a notable effect on the mortality rate of *Anopheles stephensi* larvae, indicating their potential as natural larvicides. This is an effective technique for controlling *Anopheles stephensi* that has no detrimental environmental impact.

Keywords: *Anopheles stephensi*; Larvicidal; *Nocardia*; *Streptomyces*

Introduction

Anopheles stephensi is a mosquito species that is considered a potent disease vector, as it can transmit several diseases, including malaria, lymphatic filariasis, dengue fever, chikungunya, and Zika virus, among others (1–3). Malaria threatens the lives of over a million people every year and infects an estimated 300 million

people worldwide annually (5). Djibouti (2012), Ethiopia (2016), Sri Lanka (2017), and most recently, the Republic of Sudan (2017) have all reported the presence of *A. stephensi* (1). Each year, more than 700,000 people die due to vector-borne diseases, which account for more than 17 percent of all infectious diseases (6).

In Iran, several mosquito-borne diseases can be found, including six arboviral (avian pox, bovine ephemeral, Rift Valley, Sindbis, and West Nile fever), two bacterial (anthrax and tularemia), four helminthic (*Deraiphoronema evansi* infection, dirofilariasis, wuchereriosis, and seteriasis), and two protozoal (bird malaria and human malaria) diseases (7–10).

Controlling mosquitoes is critical to preventing the spread of these diseases, but the widespread use of chemical insecticides has made mosquitoes more resistant to them (11). Efforts to control mosquitoes are primarily based on the use of natural or synthetic insecticides, but their effectiveness has been declining due to the development of resistance (12, 13). As a result, researchers are exploring alternative methods, such as the use of microbial resources to produce larvicidal agents, which are eco-friendly, biodegradable, and cost-effective (14). Microbial metabolite compounds have been observed to be very toxic to mosquitoes while having fewer adverse effects on non-specific targets (15, 16).

Actinobacteria are a group of Gram-positive bacteria responsible for producing about half of the discovered secondary metabolites with significant medicinal and commercial value (17). Several antibiotics, including streptomycin, erythromycin, and chloramphenicol, have been derived from *Actinobacteria* (18–20). Additionally, extremophilic *Actinobacteria* constitutes a valuable antibiotic source due to their rapid growth rate and propensity for their mycelium to break down and lyse quickly (21). These bacteria decompose resistant substances in soil and produce antibiotics such as aminoglycosides, erythromycin, and chloramphenicol (22, 23).

Members of the genus *Actinomycetes*, which are a type of *Actinobacteria*, produce insecticidal active compounds used to develop biocontrol of the housefly (*Musca domestica*) (24). Following the use of *Actinomycetes* insecticide, the mortality of larval and pupal stages has been reported to reach up to 90% (25). The purpose of this study was to determine the lar-

vicidal activity of metabolites isolated from the *Nocardia* (*N. fluminea*, *N. soli* and *N. pseudo-brasiliensis*) and *Streptomyces* (*S. alboflavus*) species against *An. stephensi*.

Materials and Methods

Preparation of the larvicidal solution

The larvicidal activities of four metabolites were evaluated, extracted from *Nocardia* strains N2 (C₄₀H₆₄O₁₂) (data unpublished), N4 (C₂₁H₂₈N₇O₁₄) (26), and N5 (C₁₈H₃₆O₂) (27), as well as *Streptomyces* strain S921 (C₃₂H₃₂O₁₄) (28). These metabolites were achieved using the following methods:

From randomly selected districts in Tehran (the North of Tehran, Darabad Park; the South of Tehran, Razi Park; the East of Tehran, Red Hisar Park, and the West of Tehran, Chitgar Park.), soil samples were collected at depths of 3 to 5 cm below the surface. The soil samples were stored in sterile zip-lock bags under 4 °C to maintain their sterility and to prevent them from becoming contaminated. A soil sample weighing five grams was suspended in 45 ml of physiological saline (0.9% NaCl) to prepare serial dilutions at 10-fold intervals (from 10⁻³ to 10⁻⁵ CFU/ml). Separate dilutions were cultured on actinomycete isolation agar (AIA) and potato dextrose agar (PDA) medium (Merck KGaA, Darmstadt, Germany). The plates were incubated at 28 °C for a period of 1–4 weeks. In order to isolate *Actinobacteria* strains, cream to white colonies were cultured on nutrient agar, sabouraud dextrose agar, and blood agar media (Merck, Germany), followed by paraffin baiting (29).

For the culture of the *Actinobacteria* isolates, 250 ml of brain heart infusion broth medium (BHI, Merck, Germany) was used. The culture was maintained at 30 °C in a shaker incubator (150 rpm) for five days. Following this, 10% of the medium was transferred to another flask containing 250 ml of Yeast Extract-Malt Extract (YEME) liquid medium. The flask was then incubated at 30 °C for seven days at 200

rpm. The liquid medium was centrifuged for 4 minutes at 4 °C at 12000 rpm after fermentation. In a ratio of 1:1, the supernatant was mixed with ethyl acetate and kept at room temperature for one hour. Ethyl acetate was separated from the organic phase after two layers were formed. In a rotary vacuum evaporator, the organic phase containing the anti-larval metabolites was collected and concentrated. In order to further purify the sample, silica gel column chromatography was used (255 cm, Silica gel 60, Merck). HPLC semi-preparative columns were used to purify fractions showing anti-larval activity. The metabolite structure was assessed using mass spectrometry (MS) (30).

Mass rearing of *Anopheles* mosquitoes

Anopheles stephensi mosquitoes that had already been inoculated in the Insectarium of Biology and Vector Control of Diseases Department of the School of Public Health at Tehran University of Medical Sciences (SPH-TUMS) were employed. Adult mosquitos were housed at 28±2 °C, 75%±2 humidity, and a 10–12 h light cycle (dark 10 and light 12). Artificial lighting was used to illuminate the room (fluorescent lamp). Five percent sugar water was employed to feed the adults, and guinea pigs were anesthetized and used as blood sources for direct feeding. Chlorinated water was combined with fish meal including protein and nutritional supplements (micronutrients) to enable mass rearing of the larvae.

Larvicidal Assay of *Actinobacteria* metabolites

The larvae of *An. stephensi* were obtained from the Insectarium of the Department of Biology and Vector Control of Diseases, SPH-TUMS. The effects of metabolites extracted from four isolates of *Actinobacteria* (*N. fluminea*, *N. soli*, *N. pseudobrasiliensis*, and *S. alboflavus*) on fourth-stage mosquito larvae were evaluated using a modified version of the approach from the World Health Organization (WHO) in 2005 (31).

A combination of chromatographic techniques and bioassays was used to determine

which fraction had insecticidal properties. After the extraction process, all the given chromatographical peaks were carefully collected and each fraction was tested for anti-insect activity using bioassays. The fractions showing anti-larval activity were selected for further purification and analysis using silica gel column chromatography and HPLC semi-preparative columns. The metabolite structure of the most active fraction was determined using mass spectrometry (MS). Therefore, the determination of which fraction had insecticidal properties was based on the results of the bioassays, and the fractions that showed anti-larval activity were selected for further analysis.

A total of 756 larvae were used (seven larvae per replication due to limited larvae). The experiments were performed for 24, 48, and 72 h at room temperature (28±2 °C). Dechlorinate tap water was used to make 100 mL of stock solution. Each of *Actinobacteria* metabolites in various volumes (300, 350, 400, 450, 500, 550, and 600 µl) was added to a series of containers containing 100 cc of dechlorinated water. The extracted metabolite concentration was considered as 100%, and the mentioned volumes were used from the metabolite stock. As a control, 21 larvae of the fourth stage were placed in a glass of dechlorinated water. Each larva was placed in its own glass. The number of dead larvae was counted at 24, 48, and 72 h after exposure, and the mortality rate was calculated using an average of three replications.

Data analysis

SPSS statistical software version 18 was used for statistical analysis (IBM, Armonk, NY, USA). The Abbott 's formula was used to correct mortality control (32). Toxicity data was used to calculate LC₅₀ (Lethal concentration 50) and LC₉₀ (Lethal concentration 90), which were then evaluated using appropriate analysis (33). In order to determine LC₅₀ and LC₉₀ values, probit analysis is used as a statistical method. For all statistical analyses in this study, P≤ 0.05 are considered significant.

Results

The results of anti-larval metabolite activities are presented in Tables 1–2. All metabolites had a statistically significant influence on mosquito larvae ($P < 0.05$) (Table 1). The lowest LC_{50} was observed in metabolite N5 at 72 h

(341 ppm) and the highest LC_{50} was observed at metabolite S921 at 24 h (484 ppm). The lowest LC_{90} was observed in metabolite N5 at 72 h (484 ppm) and the highest LC_{90} was observed at metabolite S921 at 24 h (701 ppm) (Table 2).

Table 1. Probit model based on time and treatment group

Group	Time		Estimate	Std. Error	Z	P	95% CI	
							Lower	Upper
N2	24	concentration	0.01	0.00	6.79	<0.001	0.00	0.01
		Intercept	-2.29	0.35	-6.54	<0.001	-2.65	-1.94
	48	concentration	0.01	0.00	7.30	<0.001	0.00	0.01
		Intercept	-2.38	0.36	-6.67	<0.001	-2.73	-2.02
	72	concentration	0.01	0.00	7.61	<0.001	0.00	0.01
		Intercept	-2.48	0.37	-6.77	<0.001	-2.84	-2.11
N4	24	concentration	0.01	0.00	7.36	<0.001	0.00	0.01
		Intercept	-2.47	0.37	-6.77	<0.001	-2.84	-2.11
	48	concentration	0.01	0.00	7.46	<0.001	0.01	0.01
		Intercept	-2.56	0.38	-6.76	<0.001	-2.94	-2.18
	72	concentration	0.01	0.00	7.67	<0.001	0.01	0.01
		Intercept	-2.39	0.36	-6.59	<0.001	-2.75	-2.02
N5	24	concentration	0.01	0.00	7.38	<0.001	0.00	0.01
		Intercept	-2.51	0.37	-6.79	<0.001	-2.88	-2.14
	48	concentration	0.01	0.00	7.78	<0.001	0.01	0.01
		Intercept	-2.61	0.38	-6.83	<0.001	-2.99	-2.23
	72	concentration	0.01	0.00	7.81	<0.001	0.01	0.01
		Intercept	-3.07	0.45	-6.86	<0.001	-3.52	-2.62
S921	24	concentration	0.01	0.00	6.39	<0.001	0.00	0.01
		Intercept	-2.86	0.42	-6.81	<0.001	-3.28	-2.44
	48	concentration	0.01	0.00	7.26	<0.001	0.00	0.01
		Intercept	-2.72	0.39	-6.96	<0.001	-3.11	-2.33
	72	concentration	0.01	0.00	7.55	<0.001	0.00	0.01
		Intercept	-2.55	0.37	-6.85	<0.001	-2.92	-2.17

*CI: Confidence Interval; N refers to *Nocardia* and S to *Streptomyces*; August 2022, Tehran Iran

Table 2. LC₅₀ and LC₉₀ values of *Actinobacteria* metabolites based on time

Group	Time	LC%	Estimate	95% CI	
				Lower	Upper
N2	24	50	417	379	455
N2	24	90	650	588	754
N2	48	50	386	350	420
N2	48	90	595	544	675
N2	72	50	370	335	402
N2	72	90	561	517	629
N4	24	50	389	354	422
N4	24	90	591	542	668
N4	48	50	376	342	407
N4	48	90	565	520	634
N4	72	50	347	310	378
N4	72	90	533	491	595
N5	24	50	390	355	422
N5	24	90	589	540	665
N5	48	50	357	323	387
N5	48	90	532	493	591
N5	72	50	341	310	368
N5	72	90	484	451	531
S921	24	50	484	449	529
S921	24	90	701	632	825
S921	48	50	416	382	449
S921	48	90	612	562	693
S921	72	50	382	347	413
S921	72	90	574	528	644

*CI: Confidence Interval; N refers to *Nocardia* and S to *Streptomyces*; August 2022, Tehran Iran

Discussion

Insecticides, including pyrethroids, organophosphates, carbamates, and organochlorines, are commonly used in malaria prevention programs to kill or repel mosquitoes that carry the malaria parasite. However, the overuse of these insecticides has led to the development of resistance in mosquito populations, which can be caused by mechanisms such as the intensification of carboxyl-cholinesterase activity, resulting in resistance to multiple classes of insecticides (34). Insecticides such as benzoylurea and the bacterium *Bacillus thuringiensis* Israelensis, which acts as a larvicide, have a limited impact

on mosquito populations (35, 36). Changes in the natural or human-made environment can significantly impact vector biology, leading to the disruption of original habitats, an increase in vector populations, and the spread of vector-borne diseases. These changes can limit the effectiveness of mosquito control measures and make it more difficult to manage disease transmission (37).

Actinomycetes have recently been identified as a valuable source of effective and efficient bioactive compounds with industrial potential (38). Mosquito populations can be managed us-

ing biological control. A study conducted in India reported that various forms of biolarvicidal agents exhibit potent LC₅₀ and LC₉₀ values against numerous mosquito-borne disease vectors (39). Previous research has demonstrated the high effectiveness of the metabolite produced by the fungus in reducing mosquito populations, with particularly notable mortality rates observed in *Culex* sp. and *Anopheles* sp. (40, 41). *Actinobacteria* are Gram-positive bacteria that produce a variety of physiologically active secondary metabolites in addition to antibiotics. Mosquito larvae can be poisoned by these metabolites (42). As a result, metabolites of *Actinobacteria* are one of the most important biological control agents for insects.

In the current study, all four investigated metabolites exhibited statistically significant anti-larval activity. Our investigation found that Actinobacterial metabolites have high potential as a complement to existing larval control measures, as they showed significant toxicity against mosquito larvae. These findings are consistent with the results of previous studies, such as the research conducted by Singh and Prakash, who demonstrated the potential of fungal metabolites as a novel strategy for filariasis and dengue control (43). Additionally, significant effects of *Lagenidium giganteum* metabolites against *Cx. quinquefasciatus* and *Ae. aegypti* have been reported (44). A study conducted in India demonstrated that extracellular secondary metabolites produced by 35 different Actinobacterial isolates were shown to have high larvicidal activity against *Culex* and *Anopheles* mosquitoes (45). The larvicidal activity of *Streptomyces* isolates against *Anopheles* larvae was previously reported (46). A study synthesized silver nanoparticles using the filtration of GRD cells of *Streptomyces* species and demonstrated larvicidal activity against *Aedes* and *Culex* larvae. They examined the larvicidal effect of Actinobacterial extracts on *Culex* larvae and found that 1000ppm concentrations of *Streptomyces* KA13-3 and *Streptomyces* KA25-A isolates killed 100% and 90% of

mosquito larvae, respectively (47). The current study's findings were agreed with the results of Tanvir et al. who isolated 21 *Actinomycetes* from *Asteraceae* plants and screened their potential to kill *Cx. quinquefasciatus* larvae in the fourth stage of development (48). A study conducted in India isolated 30 *Actinomycetes* from sediments of maritime soil and showed that *Streptomyces* isolates were highly effective against *An. stephensi* (49). Many studies have discovered that insect mortality may be caused by the release of bioactive compounds by *Actinobacteria* against *Culex* mosquito species (50). The effects of fungal and actinomycete metabolites on *Cx. quinquefasciatus*, *An. stephensi*, and *Ae. aegypti* egg, larval, and adult stages have been studied. The metabolites of three *Actinomycetes* had anti-egg activity, 35 *Actinomycetes* had larvicidal activity, and no activity against adults was discovered, according to Vijayan and Balaraman. With LC₅₀ values of 1 to 3 microliters per milliliter, two *Streptomyces* species and one *Paecilomyces* species were very active (45).

According to our investigation, the LC₅₀ and LC₉₀ values of 341 (for *Nocardia pseudobrasiliensis*) and 484 ppm (for *Streptomyces alboflavus*), respectively, were less potent. Few studies on the larvicidal activity of pure chemicals against *An. stephensi* have been reported. According a study in Tanzania, after 24 h at a concentration of 237 ppm, a himachalane sesquiterpenoid isolated from *Hugonia busseana* had moderate efficacy against *Anopheles* larvae (51). The ethanol extract of *Leucas aspera* showed an LC₅₀ of 9.70–12.73 ppm against *An. stephensi* (52). *Streptomyces alboflavus* extract was tested on *An. stephensi* larvae, as demonstrated by Balakrishnan et al. (LC₅₀ 1.3±0.09 and LC₉₀ 3.13±0.21) (53). Comparing the metabolites extracted in the study to the ones given above, they were generally more effective.

In the present study, the lowest LC₅₀ in metabolite N5 was observed in 72 h and the highest LC₅₀ in metabolite S921 in 24 hours. Also, the lowest LC₉₀ was observed in metabolite N5 at 72 h and the highest LC₉₀ was observed

in metabolite S921 at 24 hours. Karthik et al. isolated the extract of *S. gedanensis* and tested it against the larvae of *Cx. gelidus* and *Cx. tritaeniorhynchus* tested (54). Their results showed promising activity with LC₅₀ values of 108.08 ppm and 609.15 ppm. Our study agrees with their findings that *Streptomyces* metabolites have larvicidal activity against mosquito larvae. However, there were differences in the potency of the metabolites between the two studies.

Conclusion

The current investigation elucidates the diversity and distribution of metabolites in distinct actinomycete strains, as well as the anti-larval capability of selected isolates. Actinobacterial metabolites were found to be effective against *An. stephensi*. As a result, it could be exploited as an alternate source of anti-mosquito larvae. More research is needed to identify active compounds that may be employed in a broad range for mosquito control, as well as to determine the pathways of action of these compounds. The importance of larvicidal *Actinomycetes* as a useful resource for the identification of novel insecticidal compounds was investigated in this study.

Acknowledgements

The authors gratitude to Dr Sedaghat, the former Head of Department of Biology and Vector Control of Diseases, SPH-TUMS, and Dr Moosa-Kazemi, head of the department's insectarium, for their cooperation and providing larvae of *An. stephensi*.

Ethical considerations

This study was performed based on Tehran University of Medical Sciences (TUMS) Ethical Committee Guideline.

Conflict of interest statement

The authors declare that they have no competing interests.

References

1. World Health Organization (2019) Vector alert: *Anopheles stephensi* invasion and spread: Horn of Africa, the Republic of the Sudan and surrounding geographical areas, and Sri Lanka: information note. World Health Organization. Available at: <https://apps.who.int/iris/handle/10665/326595>. License: CC BY-NC-SA 3.0 IGO
2. Prevention CfDCa (2018) Parasites - Lymphatic Filariasis 2018 [updated March 16, 2018]. Available at: https://www.cdc.gov/parasites/lymphaticfilariasis/gen_info/vectors.html.
3. Yadav P, Gokhale M, Barde P, Singh DK, Mishra A, Mourya D (2003) Experimental transmission of Chikungunya virus by *Anopheles stephensi* mosquitoes. Acta Virol. 47(1): 45–47.
4. Sasi M, Rajendran R, Meenakshy V, Suresh T, Pillai RH, Kumar TD, Sugathan A, Regu K (2021) Detection of Zika virus in *Anopheles stephensi* Liston, 1901 (Diptera: Culicidae) in India-First report. Entomon. 46(4): 325–332.
5. World Health Organization (2015) Global technical strategy for malaria 2016–2030: World Health Organization.
6. World Health Organization (2020) Vector-borne diseases [updated 2 March 2020]. Available at: <https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases>
7. Azari-Hamidian S, Norouzi B, Harbach RE (2019) A detailed review of the mosquitoes (Diptera: Culicidae) of Iran and their medical and veterinary importance. Acta Trop. 194: 106–122.

8. World Health Organization (2020) World malaria report 2020: 20 years of global progress and challenges. World Health Organization. Available at: <https://apps.who.int/iris/handle/10665/337660>.
9. Naqqash MN, Gökçe A, Bakhsh A, Salim M (2016) Insecticide resistance and its molecular basis in urban insect pests. *Parasitol Res.* 115(4): 1363–1373.
10. Benelli G (2015) Plant-borne ovicides in the fight against mosquito vectors of medical and veterinary importance: a systematic review. *Parasitol Res.* 114(9): 3201–3312.
11. Vyas N, Dua K, Prakash S (2007) Efficacy of *Lagenidium giganteum* metabolites on mosquito larvae with reference to non-target organisms. *Parasitol Res.* 101(2): 385–390.
12. Singh R, Dhiman R, Mittal P (2006) Mosquito larvicidal properties of *Momordica charantia* Linn (family: Cucurbitaceae). *J Vector Borne Dis.* 43(2): 88.
13. Ahmed A, Abubakr M, Ali Y, Siddig EE, Mohamed NS (2022) Vector control strategy for *Anopheles stephensi* in Africa. *The Lancet Microbe.* 3(6): e403.
14. Ghosh A, Chowdhury N, Chandra G (2012) Plant extracts as potential mosquito larvicides. *Indian J Med Res.* 135(5): 581–598.
15. Vivekanandhan P, Karthi S, Shivakumar MS, Benelli G (2018) Synergistic effect of entomopathogenic fungus *Fusarium oxysporum* extract in combination with temephos against three major mosquito vectors. *Pathog Glob Health.* 112(1): 37–46.
16. Vivekanandhan P, Kavitha T, Karthi S, Senthil-Nathan S, Shivakumar MS (2018) Toxicity of *Beauveria bassiana*-28 mycelial extracts on larvae of *Culex quinquefasciatus* mosquito (Diptera: Culicidae). *Int J Environ Res Public Health.* 15(3): 440.
17. Takahashi Y (2004) Exploitation of new microbial resources for bioactive compounds and discovery of new actinomycetes. *Actinomycetologica.* 18(2): 54–61.
18. Blin K, Pascal Andreu V, de los Santos ELC, Del Carratore F, Lee SY, Medema MH (2019) The antiSMASH database version 2: a comprehensive resource on secondary metabolite biosynthetic gene clusters. *Nucleic Acids Res.* 47(D1): D625–D30.
19. Madigan MT, Martinko JM, Parker J (2006) Brock biology of microorganisms: Pearson Prentice Hall Upper Saddle River, NJ. 100(1): 35–46.
20. Bauer A (1966) Antibiotic susceptibility testing by a standardized single disc method. *Am J Clin Pathol.* 45: 149–158.
21. Xu L-H, Tiang Y-Q, Zhang Y-F, Zhao L-X, Jiang C-L (1998) *Streptomyces thermogriseus*, a new species of the genus *Streptomyces* from soil, lake and hot-spring. *IJSEM.* 48(4): 1089–1093.
22. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. *J Nat Prod.* 70(3): 461–477.
23. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA (2000) Practical *streptomyces* genetics: John Innes Foundation Norwich. 32: 152–158.
24. Sundarapandian S, Sundaram M, Tholkappian P, Balasubramanian V (2002) Mosquitocidal properties of indigenous fungi and actinomycetes against *Culex quinquefasciatus* Say. *Biol Control.* 16(1): 89–92.
25. Hussain A, Mostafa S, Ghazal S, Ibrahim S (2002) Studies on antifungal antibiotic and bioinsecticidal activities of some actinomycete isolates. *Afr J Biotechnol.* 10(1): 63–80.
26. Seratnahaei M, Eshraghi SS, Pakzad P, Zahraei-Ramazani A, Yaseri M (2022) Antimicrobial Activities of the Secondary Metabolite Extracted from a *Nocardia* Strain. *JABS.* 12(2): 203–114.
27. Seratnahaei M, Eshraghi SS, Pakzad P,

- Zahraei-Ramazani A, Yaseri M (2022) Antibacterial effects of bioactive metabolites extracted from *Nocardia pseudobrasiliensis*. CJES. 12 (2): 401–410.
28. Seratnaehaei M, Eshraghi SS, Pakzad P, Zahraei-Ramazani A, Yaseri M (2022) Investigation of antimicrobial effects of lipid extracted from *Streptomyces albobiflavus*. 23rd iran's international congress of microbiology.
 29. Bafghi MF, Heidarieh P, Soori T, Saber S, Meysamie A, Gheitoli K (2015) *Nocardia* isolation from clinical samples with the paraffin baiting technique. Germs. 5(1): 12–16.
 30. Kavitha A, Prabhakar P, Vijayalakshmi M, Venkateswarlu Y (2009) Production of bioactive metabolites by *Nocardia levis* MK-VL_113. Lett Appl Microbiol. 49(4): 484–490.
 31. World Health Organization (2005) Guidelines for laboratory and field testing of mosquito larvicides. World Health Organization. Available at: <https://apps.who.int/iris/handle/10665/69101>
 32. Abbott W (1987) A method of computing the effectiveness of an insecticide 1925. J Am Mosq Control Assoc. 3(2): 302–303.
 33. Finney D (1971) Probit analysis, Cambridge University Press. Cambridge, UK. Available at: <https://www.amazon.com/Probit-Analysis-David-Finney/dp/0521135907>
 34. Hemingway J, Ranson H (2000) Insecticide resistance in insect vectors of human disease. Annu Rev Entomol. 45(1): 371–391.
 35. Setha T, Chantha N, Benjamin S, Socheat D (2016) Bacterial larvicide, *Bacillus thuringiensis israelensis* strain AM 65-52 water dispersible granule formulation impacts both dengue vector, *Aedes aegypti* (L.) population density and disease transmission in Cambodia. PLoS Negl Trop Dis. 10(9): e0004973.
 36. Grosscurt AC, Tipker J (1980) Ovicidal and larvicidal structure-activity relationships of benzoylureas on the house fly (*Musca domestica*). Pestic Biochem Phys. 13(3): 249–254.
 37. Senthil-Nathan S (2020) A review of resistance mechanisms of synthetic insecticides and botanicals, phytochemicals, and essential oils as alternative larvicidal agents against mosquitoes. Front Physiol. 10: 1591.
 38. De Simeis D, Serra S (2021) Actinomycetes: A never-ending source of bioactive compounds-An overview on antibiotics production. Antibiotics. 10(5): 483.
 39. Kamaraj C, Bagavan A, Rahuman AA, Zahir AA, Elango G, Pandiyan G (2009) Larvicidal potential of medicinal plant extracts against *Anopheles subpictus* Grassi and *Culex tritaeniorhynchus* Giles (Diptera: Culicidae). Parasitol Res. 104: 1163–1171.
 40. Axtell RC, Jaronski ST, Merriam TL (1982) Efficacy of the mosquito fungal pathogen, *Lagenidium giganteum* (Oomycetes: Lagenidiales). (Proceedings and Papers of the Annual Conference of the California Mosquito and Vector Control Association, Inc., 50). pp. 41–42.
 41. Kerwin J, Washino R (1986) Ground and aerial application of the sexual and asexual stages of *Lagenidium giganteum* (Oomycetes: Lagenidiales) for mosquito control. J Am Mosq Control Assoc. 2(2): 182–189.
 42. Balaraman K (1995) Mosquito control potential of *Bacillus thuringiensis* subsp. *israelensis* and *Bacillus sphaericus*. ICMR Bulletin. 25(4): 45–51.
 43. Singh G, Prakash S (2012) Lethal effects of *Aspergillus niger* against mosquitoes vector of filaria, malaria, and dengue: a liquid mycoadulcicide. Scientific World Journal. 2012: 603984.
 44. Scholte E-J, Ng'Habi K, Kihonda J, Takken W, Paaijmans K, Abdulla S (2005) An entomopathogenic fungus for control of adult African malaria mosquitoes. Science.

- 308(5728): 1641–1642.
45. Vijayan V, Balaraman K (1991) Metabolites of fungi and actinomycetes active against mosquito larvae. *Indian J Med Res.* 93: 115–1117.
 46. Dhanasekaran D, Sakthi V, Thajuddin N, Panneerselvam A (2010) Preliminary evaluation of Anopheles mosquito larvicidal efficacy of mangrove actinobacteria. *Int J Appl Biol Pharm.* 1(2): 374–381.
 47. Rajesh K, Padmavathi K, Ranjani A, Gopinath P, Dhanasekaran D, Archunan G (2013) Green synthesis, characterization and larvicidal activity of AgNPs against *Culex quinquefasciatus* and *Aedes aegypti* larvae. *Am J Drug Discov. Dev.* 3(4): 245–253.
 48. Tanvir R, Sajid I, Hasnain S (2014) Larvicidal potential of Asteraceae family endophytic actinomycetes against *Culex quinquefasciatus* mosquito larvae. *Nat Prod Res.* 28(22): 2048–2052.
 49. Vijayakumar R, Murugesan S, Cholarajan A, Sakthi V (2010) Larvicidal potentiality of marine actinomycetes isolated from Muthupet Mangrove, Tamilnadu, India. *Int J Microbiol Res.* 1(3): 179–183.
 50. El-Khawagh M, Hamadah KS, El-Sheikh T (2011) The insecticidal activity of Actinomycete metabolites, against the mosquito *Culex pipiens*. *Egypt. Acad J Biol Sci.* 4: 103–113.
 51. Baraza LD, Joseph CC, Nkunya MH (2007) A new cytotoxic and larvicidal himachalenoid, rosanoids and other constituents of *Hugonia busseana*. *Nat Prod Res.* 21(11): 1027–1031.
 52. Kamaraj C, Bagavan A, Elango G, Zahir AA, Rajakumar G, Marimuthu S (2011) Larvicidal activity of medicinal plant extracts against *Anopheles subpictus* and *Culex tritaeniorhynchus*. *Indian J Med Res.* 134(1): 101.
 53. Balakrishnan S, Santhanam P, Srinivasan M (2017) Larvicidal potency of marine actinobacteria isolated from mangrove environment against *Aedes aegypti* and *Anopheles stephensi*. *J Parasit Dis.* 41: 387–394.
 54. Karthik L, Gaurav K, Rao K, Rajakumar G, Rahuman AA (2011) Larvicidal, repellent, and ovicidal activity of marine actinobacteria extracts against *Culex tritaeniorhynchus* and *Culex gelidus*. *Parasitol Res.* 108(6): 1447–1455.